Borysko has metastatic renal cell carcinoma and is about to…
Borysko has metastatic renal cell carcinoma and is about to begin treatment with a programmed cell death (PD)-1 inhibitor (nivolumab 240 mg IV q 2 weeks). Borysko has a central venous catheter in place for administration of nivolumab. Borysko develops a left lower leg deep vein thrombosis and is initiated on enoxaparin 1 mg/kg SC q 12 hours. How long should Borysko receive enoxaparin treatment?